Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Tirzepatide Versus Insulin Glargine In the open-label SURPASS-4 study, patients at increased cardiovascular risk on one to three oral glucose-lowering medications ( metformin sulfonylurea SGLT2 inhibitor) were randomised to once weekly tirzepatide 5, 10 or 15 mg or once daily insulin glargine (titrated following a treat-to-target algorithm) for up to 104 weeks with the primary timepoint at 52 weeks
Our obesity crisis has worsened in recent years, and most studies based on dietary changes alone or dietary changes with exercise demonstrate that patients achieve and sustain far less weight loss compared to patients who take GLP-1 angonists
Shapiro, J., Lui, H., Tron, V
Andrieu, N
US$ 28.48
US$ 26.22
US$ 22.73
US$ 29.71
US$ 21.35
US$ 27.58
US$ 25.22
US$ 29.31
US$ 24.45
US$ 22.79
US$ 22.68
US$ 20.20
US$ 24.58
US$ 25.83
